Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization

Experimental Eye Research

Volumn 79, Issue 2, 2004, Pages 275-285

  Castro, Marisol R ^a   Lutz, David ^a   Edelman, Jeffrey L ^a  

^a ALLERGAN INC   (United States)

Author keywords

angiogenesis; blood retinal barrier; choroidal neovascularization; COX inhibitor; cyclooxygenase; neovascularization; vascular endothelial growth factor

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ALBUMIN; DEXAMETHASONE; EVANS BLUE; FLUNIXIN; ICOSANOID; IMMUNOGLOBULIN FC FRAGMENT; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N(G) NITROARGININE METHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARGON LASER; ARTICLE; BLOOD RETINA BARRIER; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRAVASATION; FLUOROPHOTOMETRY; GUINEA PIG; LASER COAGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RAT; RETINA INJURY; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD-RETINAL BARRIER; CHOROIDAL NEOVASCULARIZATION; CORNEAL NEOVASCULARIZATION; CYCLOOXYGENASE INHIBITORS; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; GUINEA PIGS; INDOMETHACIN; MALE; RATS; RATS, INBRED BN; RATS, SPRAGUE-DAWLEY; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 4344663889     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2004.04.008     Document Type: Article

References (53)

1. Adamis A.P., Miller J.W., Bernal M.T., D'Amico D.J., Folkman J., Yeo T.K., Yeo K.T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118:1994;445-450
2. Adamis A.P., Shima D.T., Tolentino M.J., Gragoudas E.S., Ferrara N., Folkman J., D'Amore P.A., Miller J.W. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol. 114:1996;66-71
3. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., Nguyen H.V., Aiello L.M., Ferrara N., King G.L. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New. Engl. J. Med. 331:1994;1480-1487
4. Aiello L.P., Pierce E.A., Foley E.D., Takagi H., Chen H., Riddle L., Ferrara N., King G.L., Smith L.E. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Nat. Acad. Sci. USA. 92:1995;10457-10461
5. Alikacem N., Yoshizawa T., Nelson K.D., Wilson C.A. Quantitative MR imaging study of intraviteral sustained release of VEGF in rabbits. Invest. Ophthalmol. Vis. Sci. 41:2000;1561-1569
6. Amano S., Rohan R., Kuroki M., Tolentino M., Adamis A.P. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 39:1998;18-22
7. Ayalasomayajula S.P., Kompella U.B. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur. J. Pharmacol. 458:2002;283-289
8. Bainbridge J.W., Mistry A., De Alwis M., Paleolog E., Baker A., Thrasher A.J., Ali R.R. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther. 9:2002;320-326
9. Beubler E., Schuligoi R., Chopra A.K., Ribardo D.A., Peskar B.A. Cholera toxin induces prostaglandin synthesis via post-transcriptional activation of cyclooxygenase-2 in the rat jejunum. J. Pharmacol. Exp. Ther. 297:2001;940-945
10. Brideau C., Van Staden C., Chan C.C. In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. Am. J. Vet. Res. 62:2001;1755-1760
11. Cheng Z., Nolan A.M., McKellar Q.A. Measurement of cyclooxygenase inhibition in vivo: a study of two non-steroidal anti-inflammatory drugs in sheep. Inflammation. 22:1998;353-360
12. Collins P.D., Connolly D.T., Williams T.J. Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Br. J. Pharmacol. 109:1993;195-199
13. Cursiefen C., Rummelt C., Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea. 19:2000;526-533
14. Dempke W., Rie C., Grothey A., Schmoll H.J. Cyclooxygenase-2: a novel target for cancer chemotherapy? J. Cancer. Res. Clin. Oncol. 127:2001;411-417
15. Dowd N.P., Scully M., Adderley S.R., Cunningham A.J., Fitzgerald D.J. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J. Clin. Invest. 108:2001;585-590
16. Edelman J.L., Castro M.R. Quantitative image analysis of laser-induced choroidal neovascularization in rat. Exp. Eye Res. 71:2000;523-533
17. Edelman J.L., Castro M.R., Wen Y. Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea. Invest. Ophthalmol. Vis. Sci. 40:1999;1112-1123
18. Feletou M., Staczek J., Duhault J. Vascular endothelial growth factor and the in vivo increase in plasma extravasation in the hamster cheek pouch. Br. J. Pharmacol. 132:2001;1342-1348
19. Fosslien E. Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann. Clin. Lab. Sci. 31:2001;325-348
20. Fujii E., Irie K., Ohba K., Ogawa A., Yoshioka T., Yamakawa M., Muraki T. Role of nitric oxide, prostaglandins and tyrosine kinase in vascular endothelial growth factor-induced increase in vascular permeability in mouse skin. Naunyn Schmiedebergs Arch. Pharmacol. 356:1997;475-480
21. Futaki N., Takahashi S., Kitagawa T., Yamakawa Y., Tanaka M., Higuchi S. Selective inhibition of cyclooxygenase-2 by NS-398 in endotoxin shock rats in vivo. Inflamm. Res. 46:1997;496-502
22. Gehlbach P., Demetriades A.M., Yamamoto S., Deering T., Xiao W.H., Duh E.J., Yang H.S., Lai H., Kovesdi I., Carrion M., Wei L., Campochiaro P.A. Periocular Gene Transfer of sFlt-1 Suppresses Ocular Neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum. Gene Ther. 14:2003;129-141
23. Haynes W.L., Proia A.D., Klintworth G.K. Effect of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat. Invest. Ophthalmol. Vis. Sci. 30:1989;1588-1593
24. He H., Venema V.J., Gu X., Venema R.C., Marrero M.B., Caldwell R.B. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J. Biol. Chem. 274:1999;25130-25135
25. Kroll J., Waltenberger J. A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF - a stimulation in endothelial cells. Biochem. Biophys. Res. Commun. 265:1999;636-639
26. Kvanta A., Algvere P.V., Berglin L., Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. 37:1996;1929-1934
27. Kwak N., Okamoto N., Wood J.M., Campochiaro P.A. VEGF is major stimulator in model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 41:2000;3158-3164
28. Lai C.M., Brankov M., Zaknich T., Lai Y.K., Shen W.Y., Constable I.J., Kovesdi I., Rakoczy P.E. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum. Gene Ther. 12:2001;1299-1310
29. Liu X.H., Kirschenbaum A., Yao S., Stearns M.E., Holland J.F., Claffey K., Levine A.C. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin. Exp. Metastasis. 17:1999;687-694
30. Lopez P.F., Sippy B.D., Lambert H.M., Thach A.B., Hinton D.R. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 37:1996;855-868
31. Luna J.D., Chan C.C., Derevjanik N.L., Mahlow J., Chiu C., Peng B., Tobe T., Campochiaro P.A., Vinores S.A. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1 beta-mediated breakdown. J. Neurosci. Res. 49:1997;268-280
32. Masferrer J.L., Zweifel B.S., Manning P.T., Hauser S.D., Leahy K.M., Smith W.G., Isakson P.C., Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Nat. Acad. Sci. USA. 91:1994;3228-3232
33. Moses V.S., Hardy J., Bertone A.L., Weisbrode S.E. Effects of anti-inflammatory drugs on lipopolysaccharide-challenged and -unchallenged equine synovial explants. Am. J. Vet. Res. 62:2001;54-60
34. Murohara T., Horowitz J.R., Silver M., Tsurumi Y., Chen D., Sullivan A., Isner J.M. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation. 97:1998;99-107
35. Ozaki H., Hayashi H., Vinores S.A., Moromizato Y., Campochiaro P.A., Oshima K. Intravitreal sustained release of VEGF causes retinal neovacularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp. Eye. Res. 64:1997;505-517
36. Ozaki H., Seo M.S., Ozaki K., Yamada H., Yamada E., Okamoto N., Hofmann F., Wood J.M., Campochiaro P.A. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am. J. Pathol. 156:2000;697-707
37. Philipp W., Speicher L., Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest. Ophthalmol. Vis. Sci. 41:2000;2514-2522
38. Qaum T., Xu Q., Joussen A.M., Clemens M.W., Qin W., Miyamoto K., Hassessian H., Wiegand S.J., Rudge J., Yancopoulos G.D., Adamis A.P. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest. Ophthalmol. Vis. Sci. 42:2001;2408-2413
39. Riendeau D., Charleson S., Cromlish W., Mancini J.A., Wong E., Guay J. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can. J. Physiol. Pharmacol. 75:1997;1088-1095
40. Saishin Y., Saishin Y., Takahashi K., Lima e Silva R., Hylton D., Rudge J.S., Wiegand S.J., Campochiaro P.A. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J. Cell. Physiol. 195:2003;241-248
41. Sakamoto T., Soriano D., Nassaralla J., Murphy T.L., Oganesian A., Spee C., Hinton D.R., Ryan S.J. Effect of intravitreal administration of indomethacin on experimental subretinal neovascularization in the subhuman primate. Arch. Ophthalmol. 113:1995;222-226
42. Seo M.S., Kwak N., Ozaki H., Yamada H., Okamoto N., Yamada E., Fabbro D., Hofmann F., Wood J.M., Campochiaro P.A. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am. J. Pathol. 154:1999;1743-1753
43. Skold M., Cullheim S., Hammarberg H., Piehl F., Suneson A., Lake S., Sjogren A., Walum E., Risling M. Induction of VEGF and VEGF receptors in the spinal cord after mechanical spinal injury and prostaglandin administration. Eur. J. Neurosci. 12:2000;3675-3686
44. Smith C.J., Zhang Y., Koboldt C.M., Muhammad J., Zweifel B.S., Shaffer A., Talley J.J., Masferrer J.L., Seibert K., Isakson P.C. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Nat. Acad. Sci. USA. 95:1998;13313-13318
45. Stechschulte S.U., Joussen A.M., von Recum H.A., Poulaki V., Moromizato Y., Yuan J., D'Amato R.J., Kuo C., Adamis A.P. Rapid ocular angiogenic control via naked DNA delivery to cornea. Invest. Ophthalmol. Vis. Sci. 42:2001;1975-1979
46. Szerenyi K., Wang X.W., Lee M., Mc Donnell P.J. Topical diclofenac treatment prior to excimer laser photorefractive keratectomy in rabbits. Refract. Corneal Surg. 9:1993;437-442
47. Takahashi K., Saishin Y., Saishin Y., Mori K., Ando A., Yamamoto S., Oshima Y., Nambu H., Melia M.B., Bingaman D.P., Campochiaro P.A. Topical nepafenac inhibits ocular neovascularization. Invest. Ophthalmol. Vis. Sci. 44:2003;409-415
48. Takehana Y., Kurokawa T., Kitamura T., Tsukahara Y., Akahane S., Kitazawa M., Yoshimura N. Suppression of laser-induced choroidal neovascularization by oral tranilast in the rat. Invest. Ophthalmol. Vis. Sci. 40:1999;459-466
49. 2 release in the spinal cord. J. Neurochem. 79:2001;777-786
50. Wilkinson-Berka J.L., Alousis N.S., Kelly D.J., Gilbert R.E. COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 44:2003;974-979
51. Wong C.G., Rich K.A., Liaw L.H., Hsu H.T., Berns M.W. Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit. Curr. Eye Res. 22:2001;140-147
52. Wu H.M., Huang Q., Yuan Y., Granger H.J. VEGF induces NO-dependent hyperpermeability in coronary venules. Am. J. Physiol. 271:1996;H2735-H2739
53. Yamada M., Kawai M., Kawai Y., Mashima Y. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr. Eye Res. 19:1999;300-304